Purpose: Cerebrovascular disease (CVD) is considered a major risk factor for fatal outcome in COVID-19. We aimed to evaluate the possible association between computed tomography (CT) signs of chronic CVD and mortality in infected patients.

Materials And Methods: We performed a double-blind retrospective evaluation of the cerebral CT scans of 83 COVID-19 patients looking for CT signs of chronic CVD. We developed a rapid visual score, named CVD-CT, which summarized the possible presence of parietal calcifications and dolichosis, with or without ectasia, of intracranial arteries, areas of chronic infarction and leukoaraiosis. Statistical analysis was carried out with weighted Cohen's K test for inter-reader agreement and logistic regression to evaluate the association of in-hospital mortality with CVD-CT, chest X-ray (CXR) severity score (Radiographic Assessment of Lung Edema-RALE) for radiological assessment of pulmonary disease, sex and age.

Results: CVD-CT (odds ratio 1.6, 95% C.I. 1.2-2.1, p = 0.001) was associated with increased risk of mortality. RALE showed an almost significant association (odds ratio 1.05, 95% C.I. 1-1.1, p 0.06), whereas age and sex did not.

Conclusion: CVD-CT is associated with risk of mortality in COVID-19 patients. The presence of CT signs of chronic CVD may be correlated to a condition of fragility of the circulatory system, which constitutes a key risk factor for death in infected patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695990PMC
http://dx.doi.org/10.1007/s11547-020-01313-9DOI Listing

Publication Analysis

Top Keywords

covid-19 patients
12
signs chronic
12
chronic cvd
12
cerebrovascular disease
8
computed tomography
8
visual score
8
risk factor
8
evaluate association
8
odds ratio
8
risk mortality
8

Similar Publications

MRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial.

Blood

January 2025

Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD); University of Cologne, Faculty of Medicine and University Hos, Cologne, Germany.

The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory CLL. In total, 42 patients were enrolled and two patients with ≤2 induction cycles were excluded from the analysis population per protocol. Patients had a median of one prior therapy (range 1-5), 18 patients (45%) had already received a BTK inhibitor (BTKi), seven patients (17.

View Article and Find Full Text PDF

Corneal Perforation Associated with Pembrolizumab - A Case Report with Literature Review.

Ocul Immunol Inflamm

January 2025

Universiti Malaya Eye Research Centre (UMERC), Department of Ophthalmology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.

Purpose: To shed light on one of the ocular adverse effects related to pembrolizumab.

Method: Case report and literature review.

Result: A 53-year-old gentleman with underlying Stage III B renal cell carcinoma with lung metastasis and gout presented in June 2021 with bilateral red eyes following Coronavirus disease (COVID-19) vaccination.

View Article and Find Full Text PDF

Outcomes of Home Isolation Care Among COVID-19 Patients During the 2021 Epidemic Crisis in the Bangkok Metropolitan Region, Thailand.

Am J Public Health

January 2025

Teeraboon Lertwanichwattana and Ram Rangsin are with Phramongkutklao College of Medicine, Bangkok, Thailand. Supattra Srivanichakorn, Sairat Noknoy, and Sirinapa Siriporn Na Ratchaseema are with the Royal College of Family Physicians of Thailand, Bangkok. Nittaya Phanuphak is with the Institute of HIV Research and Innovation, Bangkok. Kitti Wongthavarawat is with the National Science and Technology Development Agency, Bangkok. Arunotai Siriussawakul, Varalak Srinonprasert, and Pattara Leelahavarong are with the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok. Parawee Chevaisrakul and Putthapoom Lumjiaktase are with the Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok. Aree Kumpitak is with the Thai Network of People Living With HIV, Bangkok. Nopphan Phromsri is with the Human Settlement Foundation, Bangkok. Yupadee Sirisinsuk is with the Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok. Pongtorn Kietdumrongwong is with the Bangkok Dusit Medical Services, Bangkok. Apinun Aramrattana is with the Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

To determine the overall mortality and risk factors of COVID-19 patients who were admitted to the Home Isolation (HI) program in Bangkok, Thailand, during the epidemic crisis in 2021. We conducted a retrospective cohort study using the data from a government telehealth application from July to December 2021. The vital status was verified from the government database on September 20, 2022.

View Article and Find Full Text PDF

Long-term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2,333,496 Patients from the TriNetX Network.

J Clin Endocrinol Metab

January 2025

Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China.

Context: Reports on long-term thyroid dysfunction following COVID-19 vaccination are limited. Understanding the risk of subacute thyroiditis, hyperthyroidism, and hypothyroidism in vaccinated individuals is crucial for post-vaccination monitoring.

Objective: This study evaluated the risk of thyroid dysfunction in COVID-19 vaccinated individuals compared to unvaccinated individuals using a large cohort.

View Article and Find Full Text PDF

General practice registrar evaluation of long COVID in patients presenting with fatigue.

Aust J Prim Health

January 2025

Discipline of General Practice, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia.

Background Long COVID is a new and prevalent condition defined by persistent symptoms following acute COVID-19 infection. While increasing resources are being directed to management, there is little evidence on how general practitioners (GPs) have changed their assessment and differential diagnosis of patients with potential long COVID symptoms including fatigue. This study aimed to examine how often GP registrars consider long COVID in patients presenting with fatigue, how often they think long COVID might be the cause for fatigue, and patient, registrar, practice, and consultation factors associated with these outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!